15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic cardiomyopathy living in Quebec and Alberta and covered under the federal government Non-Insured Health Benefits (NIHB) Program. 

Camzyos (mavacamten capsules), a first in class oral cardiac myosin inhibitor for the treatment of oHCM is now included on the Régie de l'assurance maladie du Québec (RAMQ) List of Medications, the Alberta Drug Benefits List and available through the Indigenous Services Canada NIHB drug plan for coverage for patients who meet certain eligibility criteria.

Read BMS press release